LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
Work
Year: 2023
Type: article
Source: Annals of Oncology
Institutions Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Seoul National University Hospital, Institut Català d'Oncologia, Institut d'Investigació Biomédica de Bellvitge +18 more
Cites: 1
Cited by: 31
Related to: 10
FWCI: 9.331
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze